ANIX · Anixa Biosciences Inc · Metrics
Market Cap
$101.22M
Shares
34.02M
ANIX metrics
57 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$2.90
Market cap
$101.22M
Price action
20 metricsPrice change (1W)
-11.8%
Price change (30D)
-5.5%
Price change (3M)
+23.8%
Price change (6M)
+7.7%
Price change (YTD)
-1.6%
Price change (1Y)
+3.4%
Trailing year
Price change (5Y)
-43.5%
52-week high
$5.22
52-week low
$2.35
Change from 52-week high
-41.2%
Change from 52-week low
+30.6%
Annualized volatility
74.0%
Annualized volatility (3M)
66.1%
Beta
1.6
RSI (14D)
37.5
Price vs SMA 50
-8.1%
Price vs SMA 200
-3.0%
Avg volume (3M)
270,554
Relative volume
1.4
Average dollar volume
$870,790
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
34.02M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
7.0
reciprocal yield 14.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-6,586.2%
Trailing 12 months
Net margin
-5,978.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$10.68M
Net income (TTM)
−$10.03M
Trailing 12 months
Diluted EPS (TTM)
$-0.30
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.3%
Year over year · more shares
Revenue CAGR (3Y)
-25.7%
Revenue CAGR (5Y)
-3.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-69.3%
Return on assets
-67.5%
Debt / equity
—
Current ratio
9.8
EBITDA (TTM)
−$18.56M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.48M
Total assets
$14.87M
Total debt
$370,181
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.12M
Capital expenditures (TTM)
$15,791
R&D (TTM)
$4.56M
SG&A (TTM)
$4.90M
Stock compensation (TTM)
$3.09M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
64
13F filer change QoQ
+2
Institutional ownership
15.9%
Short interest
3 metricsShort interest
2.9%
Latest settlement · 6.3 days to cover
Days to cover
6.3d
Short-squeeze score
54 / 100
Insider activity
2 metricsNet insider buying (90D)
$199,785
Insider-sentiment score
88 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
715446
CUSIP
03528H109
13F (30d)
38 filings
38 filers
Visit website
Investor relations